JAMA Dermatology Current Issue http://www.elizeaboutbeauty.com/journals/jamadermatology en-us Mon, 01 Mar 2021 00:00:00 GMT Wed, 17 Mar 2021 11:43:30 GMT Silverchair jamams@jamanetwork.org support@www.elizeaboutbeauty.com JAMA Dermatology http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2777771 Mon, 01 Mar 2021 00:00:00 GMT Mission Statement: JAMA Dermatology publishes information concerning the skin, its diseases, and their treatment. Its mission is to explicate the structure and function of the skin and its diseases and the art of using this information to deliver optimal medical and surgical care to the patient. We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician’s ability to diagnose and treat skin disorders. This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease. We believe that knowledge derived from well-designed clinical trials and studies of cost-effectiveness are especially important for improving the practice of dermatology. Studies that increase the understanding of the outcome of treatment or the means by which the burden of dermatologic disease can be measured and reduced to promote the health of patients with skin disease will receive special priority. The journal regularly publishes reports on clinical investigations, editorials, and reviews. It also features reports and discussions on clinicopathologic correlations; clinical disorders of unique didactic value; pharmacologic, medical and surgical therapeutics; and ethical, moral, socioeconomic, and political issues. 157 3 264 264 10.1001/jamadermatol.2020.3866 2777771 Surgical Interventions for Vitiligo http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2776177 Mon, 01 Mar 2021 00:00:00 GMT Ju H, Bae J, Lee R, et al. This systematic review and meta-analysis investigates the treatment response of different surgical modalities in patients with vitiligo. 157 3 307 316 10.1001/jamadermatol.2020.5756 2776177 The Role of Dermatologists in the Early HIV/AIDS Epidemic http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775819 Mon, 01 Mar 2021 00:00:00 GMT Milbar H, James WD. This Special Communication reviews dermatology’s role in the investigation and treatment of HIV/AIDS over the past 40 years. 157 3 326 329 10.1001/jamadermatol.2020.5545 2775819 Androgenetic Alopecia Among Transgender and Gender-Diverse Patients Treated With Masculinizing Hormone Therapy http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775818 Mon, 01 Mar 2021 00:00:00 GMT Thoreson N, Grasso C, Potter J, et al. This cohort study examines the proportion of transgender and gender-diverse individuals patients receiving masculinizing hormone therapy who developed androgenetic alopecia. 157 3 348 349 10.1001/jamadermatol.2020.5475 2775818 Hypertrichotic Plaque in a 17-Month-Old Boy http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775817 Mon, 01 Mar 2021 00:00:00 GMT Kabbur G, Ravishankar A, Maguiness S. A 17-month-old boy presents with a 15 ×?-cm indurated plaque with hypertrichosis on the left lower back in addition to blue-gray patches on the back and right hip and a small café au lait macule on the right lower back. The patient’s history is significant for dermal melanocytosis of the back and hip, increased head circumference, and expressive language delay. What is your diagnosis? 157 3 342 343 10.1001/jamadermatol.2020.5665 2775817 Allergic Contact Dermatitis http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775575 Mon, 01 Mar 2021 00:00:00 GMT Adler BL, DeLeo VA. This Patient Page describes the symptoms, possible causes, and treatment of allergic contact dermatitis. 157 3 364 364 10.1001/jamadermatol.2020.5639 2775575 Trends and Clinician Variability in Potassium Monitoring of Women Treated With Spironolactone http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775574 Mon, 01 Mar 2021 00:00:00 GMT Barbieri JS, Margolis DJ, Mostaghimi A. This cohort study assesses the change in the rates of potassium level monitoring from 2008 to 2018 by clinicians overall and stratified by dermatologists, internists, nurse practitioners, and physician assistants in healthy young women treated for acne with spironolactone. 157 3 296 300 10.1001/jamadermatol.2020.5468 2775574 Photodynamic Therapy and Medicare Expenditures—Reply http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775573 Mon, 01 Mar 2021 00:00:00 GMT Cheraghlou S, Feng H, Cohen JM. In Reply We appreciate the comments of Ms Lim and Dr Weinstock on our analysis of recent trends in the access and cost of photodynamic therapy (PDT) in the Medicare population. While we agree that the present literature does not indicate that PDT is the most effective field therapy for actinic keratoses (AKs), it has several features that make it a valuable treatment modality for a subset of patients. In particular, the irritation caused by fluorouracil cream (FC) can be a substantial deterrent for patients' continued use of the medication. Indeed, studies directly comparing patient preferences between FC and PDT have found that most patients prefer PDT. As an in-office procedure, PDT also avoids certain challenges with adherence that are inherent to outpatient topical therapies and especially problematic for treatments that cause local irritation. 157 3 357 357 10.1001/jamadermatol.2020.4657 2775573 Treatment of Grover Disease With Dupilumab http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775572 Mon, 01 Mar 2021 00:00:00 GMT Butler DC, Kollhoff A, Berger T. This case report describes 3 patients with focal acantholytic dyskeratosis. 157 3 353 356 10.1001/jamadermatol.2020.5097 2775572 Photodynamic Therapy and Medicare Expenditures http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775571 Mon, 01 Mar 2021 00:00:00 GMT Lim RK, Weinstock MA. To the Editor We read with interest the article by Cheraghlou et al regarding trends in the cost of and access to photodynamic therapy (PDT) among Medicare beneficiaries. The authors note an increase in the number of dermatologists offering PDT and an annual growth rate of approximately 4% in Medicare reimbursements for PDT. They suggest that increased use of PDT may reduce the occurrence of keratinocyte cancers, and thus lead to lower Medicare expenditures. However, the existing literature indicates that PDT is not the most cost-efficient, nor most effective, preventive measure for keratinocyte cancer or for actinic keratosis (AK). To date, to our knowledge, only 1 randomized trial has documented an AK treatment that is effective for keratinocyte cancer reduction. 157 3 356 357 10.1001/jamadermatol.2020.5422 2775571 Hair Removal for Patients Undergoing Feminizing Surgeries in Oregon’s Medicaid Program http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775570 Mon, 01 Mar 2021 00:00:00 GMT Downing JM, Yee K, Dy G. This cohort study assessed the use of preoperative hair removal among transgender individuals assigned male sex at birth enrolled in Oregon’s Medicaid program and their clinicians. 157 3 346 348 10.1001/jamadermatol.2020.5419 2775570 Shared Decision-making in Dermatology http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775504 Mon, 01 Mar 2021 00:00:00 GMT Morrison T, Johnson J, Baghoomian W, et al. This scoping review discusses the use of shared decision-making between patients and physicians in dermatology practice. 157 3 330 337 10.1001/jamadermatol.2020.5362 2775504 Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775503 Mon, 01 Mar 2021 00:00:00 GMT Kimball AB, Guenther L, Kalia S, et al. This cohort study reports pregnancy outcomes observed among women enrolled in the Psoriasis Longitudinal Assessment and Registry. 157 3 301 306 10.1001/jamadermatol.2020.5595 2775503 Pharmacogenomics of Fluoropyrimidines—a Personalized Approach for Treating and Preventing Keratinocyte Carcinomas—Reply http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775502 Mon, 01 Mar 2021 00:00:00 GMT Schauder DM, Nijhawan RI. In Reply We thank Ikediobi for her interest in our study, as well as for her insightful suggestions on the design of future work in this area using her expertise in pharmacogenomics. The primary goal of our study was to systematically review what has been published on capecitabine’s association with keratinocyte carcinomas. In doing so, we highlighted not only the potential of capecitabine as a likely underused chemopreventative modality for patients with a high risk of developing keratinocyte carcinomas, particularly solid organ transplant recipients, but also the need for a prospective trial. We appreciate Ikediobi’s important points regarding how such a study should be designed. 157 3 358 358 10.1001/jamadermatol.2020.5246 2775502 Pharmacogenomics of Fluoropyrimidines—A Personalized Approach for Treating and Preventing Keratinocyte Carcinomas http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775501 Mon, 01 Mar 2021 00:00:00 GMT Ikediobi O. To the Editor I read the article by Schauder et al and thank the authors for highlighting this important area of therapeutic research. The authors state that the potential widespread use of capecitabine for chemoprevention and treatment of keratinocyte carcinomas may be severely hampered by its treatment-related toxicity. They conclude that future prospective trials are warranted, but do not provide any direction on how those trials should be designed. In this era of genomic-driven medicine, it would be important for the authors to acknowledge several key factors in trial design, including (1) the use of dihydropyrimidine dehydrogenase (DPYD) genetic testing in reducing capecitabine-related toxicity and (2) DPYD testing in ethnically diverse populations. 157 3 357 358 10.1001/jamadermatol.2020.5542 2775501 Shared Decision-Making in Dermatologic Care http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775500 Mon, 01 Mar 2021 00:00:00 GMT Coughlin CC, Politi MC. In this issue of JAMA Dermatology, Morrison and colleagues present a scoping literature review of shared decision-making (SDM) in dermatology. The authors analyze 29 articles about SDM and/or patient decision aids for dermatologic conditions. Their analysis suggests that SDM is useful and desired by almost all patients and many clinicians, but more work should explore how best to implement SDM into routine dermatologic care. 157 3 271 272 10.1001/jamadermatol.2020.5360 2775500 Follicular Papules in a Linear Distribution on a Child’s Face http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775499 Mon, 01 Mar 2021 00:00:00 GMT Carvajal-Zuñiga C, Jerez J, Rozas-Muñoz E. A girl younger than 2 years presented with a 1-year history of slightly pruritic lesions involving her face. What is your diagnosis? 157 3 340 341 10.1001/jamadermatol.2020.5588 2775499 Factors Associated With Acne Among Transgender Patients Receiving Masculinizing Hormones http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775154 Mon, 01 Mar 2021 00:00:00 GMT Thoreson N, Park JA, Grasso C, et al. This cohort study examines the prevalence of acne in transgender individuals initiating masculinizing hormone therapy. 157 3 290 295 10.1001/jamadermatol.2020.5347 2775154 Association of Topical Corticosteroids and Risk of Osteoporosis and Major Osteoporotic Fractures http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775153 Mon, 01 Mar 2021 00:00:00 GMT Egeberg A, Schwarz P, Harsløf T, et al. This nationwide cohort study examines the association between cumulative exposure to potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fracture among adults in Denmark. 157 3 275 282 10.1001/jamadermatol.2020.4968 2775153 Moderate-to-Severe Acne and Mental Health Symptoms in Transmasculine Persons http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775152 Mon, 01 Mar 2021 00:00:00 GMT Braun H, Zhang Q, Getahun D, et al. This survey study examines the association between acne and mental health outcomes for transmasculine persons who have received testosterone. 157 3 344 346 10.1001/jamadermatol.2020.5353 2775152 White Piedra http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775151 Mon, 01 Mar 2021 00:00:00 GMT Bieber A, Pomeranz M, Kim RH. This case report describes white and tubular concretions of proteinaceous materials that were tightly adherent to the hair shaft. 157 3 339 339 10.1001/jamadermatol.2020.4266 2775151 Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis—Dose and Duration Matter http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2775150 Mon, 01 Mar 2021 00:00:00 GMT Jackson RD. Glucocorticoids are used by an estimated 0.5% to 1.0% of adults for management of a range of conditions, from allergies and inflammatory diseases to cancer. Glucocorticoid use increases with age: more than 3% of adults older than 50 years and 5.2% older than 80 years use glucocorticoids. Despite the availability of a growing number of medications to modulate immune function and/or inflammation, evidence from the Danish National Patient Registry suggests that the prevalence of glucocorticoid use has remained remarkably stable for 17 years (1999-2016). Thus, any noteworthy adverse effects associated with glucocorticoid use could have substantial consequences not only for the individual, but also for public health. 157 3 269 270 10.1001/jamadermatol.2020.4967 2775150 Resisting Racism in Dermatology http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774800 Mon, 01 Mar 2021 00:00:00 GMT Lester JC, Taylor SC. This Viewpoint discusses how dermatologists can work together to dismantle structural racism in dermatology. 157 3 267 268 10.1001/jamadermatol.2020.5029 2774800 Risk of Anal Carcinoma After Anogenital Warts in Adults Living With HIV http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774799 Mon, 01 Mar 2021 00:00:00 GMT Arnold JD, Byrne ME, Monroe AK, et al. This cohort study assesses the risk of developing anal carcinoma in adults living with HIV who have a history of anogenital warts. 157 3 283 289 10.1001/jamadermatol.2020.5252 2774799 Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774596 Mon, 01 Mar 2021 00:00:00 GMT Iorizzo M, Haneke E. This case report describes opaque trachyonychia of all fingernails. 157 3 352 353 10.1001/jamadermatol.2020.4555 2774596 Levamisole-Induced Vasculopathy http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774593 Mon, 01 Mar 2021 00:00:00 GMT LQpez-S֙nchez C, Rozas-Muñoz E, Mir-Bonafé J. This case report describes man in his 40s who was a long-term cocaine user who presented with rapidly progressive painful skin lesions and malaise. 157 3 338 338 10.1001/jamadermatol.2020.4011 2774593 Postoperative Radiotherapy for Cutaneous Squamous Cell Carcinoma in Patients With Microscopic Residual Disease http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774508 Mon, 01 Mar 2021 00:00:00 GMT Leus AG, Perrels ED, Halmos GB, et al. This case series assesses data from patients with microscopic residual disease to examine postoperative radiotherapy outcomes. 157 3 349 352 10.1001/jamadermatol.2020.4828 2774508 Changes in Use of Radiotherapy Among Dermatologists From 2013 to 2017 http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774506 Mon, 01 Mar 2021 00:00:00 GMT Nguyen KD, Chen HW, Adamson AS. This cross-sectional study examines changes in the use of radiotherapy, including superficial radiotherapy and electronic brachytherapy, over time by dermatologists. 157 3 322 325 10.1001/jamadermatol.2020.4931 2774506 Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome http://www.elizeaboutbeauty.com/journals/jamadermatology/fullarticle/2774504 Mon, 01 Mar 2021 00:00:00 GMT Lewis DJ, Haun PL, Samimi SS, et al. This case series assesses the preliminary efficacy and tolerability of brentuximab vedotin for Sézary syndrome. 157 3 317 321 10.1001/jamadermatol.2020.4901 2774504 4887王中王鉄算 盘开奖结果小说